CoChat

The DOI matches its Crossref record; 99 of the 100 references it cites were found in a registry or an index.

Tirzepatide: A Systematic Update

Open access

Abstract

Tirzepatide is a new molecule capable of controlling glucose blood levels by combining the dual agonism of Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptors. GIP and GLP1 are incretin hormones: they are released in the intestine in response to nutrient intake and stimulate pancreatic beta cell activity secreting insulin. GIP and GLP1 also have other metabolic functions. GLP1, in particular, reduces food intake and delays gastric emptying. Moreover, Tirzepatide has been shown to improve blood pressure and to reduce Low-Density Lipoprotein (LDL) cholesterol and triglycerides. Tirzepatide efficacy and safety were assessed in a phase III SURPASS 1–5 clinical trial program. Recently, the Food and Drug Administration approved Tirzepatide subcutaneous injections as monotherapy or combination therapy, with diet and physical exercise, to achieve better glycemic blood levels in patients with diabetes. Other clinical trials are currently underway to evaluate its use in other diseases. The scientific interest toward this novel, first-in-class medication is rapidly increasing. In this comprehensive and systematic review, we summarize the main results of the clinical trials investigating Tirzepatide and the currently available meta-analyses, emphasizing novel insights into its adoption in clinical practice for diabetes and its future potential applications in cardiovascular medicine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms232314631

Cites

99 of 100 references verified1 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Structure of Tirzepatide (39 amino acids), a dual GIP/GLP-1 receptor agonist (twincretin) that has two non-coded amino acid residues (α-aminoisobutyric acid) at positions 2 and 13 and is acylated on K20 with a γGlu-2×OEG linker and C18 fatty diacid moiety.
Figure 1 Structure of Tirzepatide (39 amino acids), a dual GIP/GLP-1 receptor agonist (twincretin) that has two non-coded amino acid residues (α-aminoisobutyric acid) at positions 2 and 13 and is acylated on K20 with a γGlu-2×OEG linker and C18 fatty diacid moiety.CC BY · PubMed Central
Figure 2 Mean variations in systolic blood pressure (SBP) with Tirzepatide vs. placebo/other drugs in the SURPASS-1 [38], SURPASS-2 [41], SURPASS-3 [44], SURPASS-4 [52], SURPASS-5 [56], and SURMOUNT-1 [66] clinical trials.
Figure 2 Mean variations in systolic blood pressure (SBP) with Tirzepatide vs. placebo/other drugs in the SURPASS-1 [38], SURPASS-2 [41], SURPASS-3 [44], SURPASS-4 [52], SURPASS-5 [56], and SURMOUNT-1 [66] clinical trials.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 100 references

Research works printed but not linked: 1

  1. Santulli, 2022, Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes, N. Engl. J. Med., 386, e17

Cited by

See all 165

Metadata

Authors
Forzano, I., Varzideh, F., Avvisato, R., Jankauskas, S. S., Mone, P., & Santulli, G.
Affiliations
  • Federico II University Hospital (IT)
  • Albert Einstein College of Medicine (US)
Corresponding author
Santulli, Gaetano
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-11-23
Volume
23
Issue
23
Pages
14631
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4309844212
Cited by
118
References
100
Citations by year
2026: 30 · 2025: 45 · 2024: 32 · 2023: 10 · 2022: 1
FWCI
3.13
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Archivio Istituzionale della Ricerca - Università degli Studi del Molise (submittedVersion)
Funders
  • National Institutes of Health (NIH) (R01-DK123259, R01-DK033823, R01-HL159062, R01HL164772, R01-HL146691, T32-HL144456, UL1TR002556-06, AHA-22POST995561, AHA-21POST836407)
  • National Heart, Lung, and Blood Institute (R01-DK123259, R01-DK033823, R01-HL159062, R01HL164772, R01-HL146691, T32-HL144456, UL1TR002556-06, AHA-22POST995561, AHA-21POST836407)
  • National Center for Advancing Translational Sciences (R01-DK123259, R01-DK033823, R01-HL159062, R01HL164772, R01-HL146691, T32-HL144456, UL1TR002556-06, AHA-22POST995561, AHA-21POST836407)
  • Diabetes Action Research and Education Foundation (R01-DK123259, R01-DK033823, R01-HL159062, R01HL164772, R01-HL146691, T32-HL144456, UL1TR002556-06, AHA-22POST995561, AHA-21POST836407)
  • American Heart Association (R01-DK123259, R01-DK033823, R01-HL159062, R01HL164772, R01-HL146691, T32-HL144456, UL1TR002556-06, AHA-22POST995561, AHA-21POST836407)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
tirzepatide, incretins, type 2 diabetes, glycemic control, SURPASS trials, LDL cholesterol, triglycerides, blood pressure, cardiovascular risk, drug safety, subcutaneous injection
MeSH terms
Glucagon-Like Peptide-1 Receptor, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glucose, Humans, Hypoglycemic Agents, Glucagon-Like Peptide 1, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tirzepatide: A Systematic Update. https://app.cochat.ai/papers/10.3390/ijms232314631
The paper
Forzano, I., Varzideh, F., Avvisato, R., Jankauskas, S. S., Mone, P., & Santulli, G. (2022). Tirzepatide: A Systematic Update. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms232314631

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.